



ALPHATOPICS  
CONFERENCE

CONFERENCE "DEVELOPMENT OF CANNABIS-BASED  
HERBAL MEDICINAL PRODUCTS IN EUROPE"

12th and 13th March 2025 in Berlin



**Success factors for the development of cannabis-based drugs:  
Join the dialogue between authorities, industry and science!**

We have addressed this topic and brought together experts from regulatory authorities and industry in various fields to provide a consolidated overview of requirements, hurdles and success factors in development projects with cannabis-based medicinal products.

With our event we also aim to engage with future applicants to contribute to the success of such projects.

**Our conference creates a platform for the exchange of knowledge and experiences for the successful development of innovative, cannabis-based medicinal products in Europe.**



**ALPHATOPICS  
CONFERENCE**



## INTRODUCTION

In Europe, cannabis-based medicines are prescribed and dispensed as magistral formulations for patients or, in some member states, they can be prescribed for specific indications based on special licences. Sativex® is the only cannabis-based medicinal product with a regular marketing authorisation in Europe. This situation is certainly only temporary, and in the next few years further regularly authorised cannabis-based medicinal products will come onto the market. These products are "herbal medicinal products", for which there are a number of specific requirements in Europe.

The active constituents used as API in the preparations are present as multicomponent mixtures, mostly as extracts. This has implications for non-clinical and clinical development and specifically for CMC aspects. The focus here lies on ensuring batch-compliant traceability

for the preparations to non-clinical and clinical batches, and a number of particularities arise that must be taken into account in non-clinical and clinical investigations.

Furthermore, there is always a risk of comparing 'apples with oranges' when referring to bibliographic data that may have been obtained with preparations that have different patterns of constituents than the preparation to be developed and authorised. This also applies to "real world evidence" and "real world data". Finally, there are special considerations regarding the possibilities of data exclusivity and the establishment of IP protection. For products for nasal or inhaled administration, which can be useful for a rapid onset of action in acute situations, the particularities for combination products must be taken into account.





# Cannabis Conference 2025 - Day 1

UHRZEIT	THEMA	REFERENT/INNEN
09:00 - 09:45	Come Together & Registration	
09:45 - 10:00	<b>Introduction</b>	Dr. Markus Veit (Alphatopics GmbH)
10:00 - 11:00	<b>Cannabis as authorised medicinal product – pathways for obtaining marketing authorisations in Europe</b>	Dr. Jacqueline Wiesner (BfArM (invited, internal approval in progress))
11:00- 11:45	<b>Regulatory use of "real world data" and "real world evidence" for cannabis medicines – opportunities and limitations</b>	Dr. Simone Breikopf (DGPharMed e. V.)
11:45- 12:30	<b>The roadmap to marketing authorisation – points to consider from QTPP to the submission of MAAs for herbal medicinal products in the EU limitations</b>	Dr. Armin Prasch (Trias Pharma GmbH)
12:30 - 13:30	LUNCH	
13:30 -14:15	<b>Considerations for non-clinical development for cannabis-based medicines</b>	Dr. Marcel Daas (Dr. Ebeling & Assoc. GmbH)
14:15 - 15:00	<b>Submission of clinical trial applications – points to consider and success factors</b>	Dr. Markus Veit (Alphatopics GmbH)
15:00 - 15:30	COFFEE BREAK	
15:30 -16:15	<b>Navigating the future of clinical development</b>	Ana Serrato (Avextra Pharma GmbH)



## PROGRAMME

THURSDAY, MARCH 13, 2025

## Cannabis Conference 2025 - Day 2

UHRZEIT	THEMA	REFERENT/INNEN
09:00 - 10:00	<b>CMC considerations for cannabis-based herbal medicinal products</b>	Dr. Markus Veit (Alphatopics GmbH)
10:00 - 10:45	<b>Formulation development for oral dosage forms of cannabis-based medicinal products</b>	Dr. Norbert Pöllinger (Glatt Pharmaceutical Services GmbH & Co. KG)
10:45 - 11:15	COFFEE BREAK	
11:15 - 12:00	<b>Considerations for pharmaceutical development of cannabis-based drug-device combination products for inhalation</b>	Thomas Weuthen (Actarmo Medical GmbH)
12:00 - 13:00	<b>Regulatory pathway for drug-device combination products (DDCPs)</b>	Dr. Armin Prasch (Trias Pharma GmbH) & Dr. Markus Veit (Alphatopics GmbH)
13:00 - 14:00	LUNCH	
14:00 - 14:45	<b>Cannabis extracts – what is state of the art?</b>	Michael Sassano (Somai Pharmaceuticals)
14:45 - 15:30	<b>Regulatory data protection and possibilities and limitations of IP protection in development projects</b>	Dr. Xenia Boergen (European Patent Attorney, Boergen Rechtsanwaltskanzlei)
15:30 - 16:30	<b>Panel and wrap-up with all speakers</b>	



## Cannabis Conference 2025

### **Cannabis as authorised medicinal product – pathways for obtaining marketing authorisations in Europe**

**10:00 - 11:00**

- How to get started and who to ask?
- Pharmacopoeia monographs – why and when are they helpful?
- Cannabis preparations and THC/CBD – is there a difference?
- Which submission options exist?
- Application options: Full application, mixed applications, well-established use and/or any other options?
- Usage of "real world data" and "real world evidence" and non-interventional studies?

Dr. Jacqueline Wiesner  
(BfArM (invited, internal approval in progress))

In the EU marketing authorisations can be obtained in individual member states, in a group of member states or in the entire EU and the countries of the European Economic Area. There are various ways in which bibliographic data can be used in such applications. Recently, the regulatory use of so-called "real world data" and the resulting "real world evidence" has also been discussed. The presentation will discuss the relevant aspects in this context as well as the framework conditions for the various authorisation routes.

---

### **Regulatory use of "real world data" and "real world evidence" for cannabis medicines – opportunities and limitations**

**11:00 - 11:45**

- First EMA RWE Study on Cannabis flos
- RWD sources already accepted by EMA
- RWE/RWD to support regulatory decisions
- RWE/RWD to support clinical development
- Data quality considerations

Dr. Simone Breitkopf  
(DGPharMed e. V.)

Today, the marketing authorisation of medicinal products is based on prospective clinical studies. The extent to which evidence can be established with data from real-world clinical practice (real-world evidence), which can be used supportively in the context of marketing authorisations or for the application for clinical trials in order to evaluate the safety and efficacy and thus the benefit-risk profile of a new medicinal product, is currently being discussed. Such an approach is particularly relevant for cannabis-based medicinal products, since many RWD on the use of cannabis and cannabis-based preparations are available in different indications. In this context, the origin of these data and their quality is of great importance. The presentation intends to highlight the possibilities and advantages, but also the limitations of RWD and RWE studies. For cannabis-based medicinal products these issues are of great importance for development projects.



# Cannabis Conference 2025

## The roadmap to marketing authorisation – points to consider from QTPP to the submission of MAAs for herbal medicinal products in the EU

**11:45 - 12:30**

- The QTPP for cannabis-based medicinal products
- Pharmaceutical development
- Framework for non-clinical and clinical development
- Decision gates, partners and contracts needed
- Establishment and control of supply chain
- Scientific advice from authorities
- Investigational medicinal products

Dr. Armin Prasch  
(Trias Pharma GmbH)

This presentation will give an introduction into a quality-by-design (QbD)-driven development approach which defines critical material attributes (CMA) and critical process parameters (CPP) resulting in an individual quality target product profile (QTPP) for a cannabis-based herbal medicinal product. Standard development activities for a pharmaceutical development project, starting with the characterisation and specification of the active pharmaceutical ingredient (API), its drug product formulation, manufacturing steps, through to the provision of clinical trial medication ("investigational medicinal product", IMP) as well as full analytical characterisation and testing will be described. From API supply through pharmaceutical development to the provision and release of IMP and clinical testing at a CRO various parties need to be responsibly involved as part of an integrated development roadmap. An overview of related integrated activities with decision gates and contractually defined responsibilities regarding quality and supply chain aspects will be given.

---

## Considerations for non-clinical development for cannabis-based medicines

**13:30 - 14:15**

- Non-clinical safety data needed
- Under which premises and to what extent can bibliographic non-clinical safety data be used?
- Points to consider for justifying data on the mode of action of herbal extracts
- Non-clinical pharmacology data needed

Dr. Marcel Daas  
(Dr. Ebeling & Assoc.  
GmbH)

Non-clinical development includes the establishment of pharmacological and toxicological data. A number of particularities arise from the fact that cannabis-based active ingredients used in herbal medicinal products represent multi-component mixtures. This not only requires comprehensive phytochemical characterisation but also has a number of implications for the design of experiments. Data collected in cell-free and cellular systems, i.e. not with intact tissue or not in the intact organism, are in many cases of limited value, since the bioavailability of the substances and mixtures investigated in the preparations is not known and biotransformation processes in the intact organism often result in metabolites that are then bioavailable instead of the genuine compounds. Conclusive data on the pharmacological mode of action can therefore not be established in many cases for herbal products. When evaluating safety data, it must always be shown whether the tested substances or preparations are representative of the medicinal product to be administered later.



## Cannabis Conference 2025

### Submission of clinical trial applications – points to consider and success factors 14:15 - 15:00

- Clinical Trials Regulation 536/214
- Clinical Trials Information System (CTIS)
- Electronic vs. paper-based submission
- Herbal IMPD

Dr. Markus Veit  
(Alphatopics GmbH)

Clinical trials are an indispensable part of the development and authorisation of medicinal products. They are designed to prove the efficacy of new medicinal products and to determine their safety and tolerability. In the EU, we are currently in a transitional phase with regard to the authorisation of clinical trials. Regulation (EU) No. 536/2014 ("Clinical Trial Regulation", CTR) changes the authorisation procedure for clinical drug trials in many areas. In future, applications will be submitted via an EU-wide portal, the Clinical Trials Information System (CTIS). The CTIS serves as a central point of contact for the submission of information on clinical trials in the EU and the European Economic Area. Detailed information on all clinical trials conducted in the EU and EEA can be accessed via the public website once the trials have been submitted and authorised in the CTIS. In future, multinational clinical trials in the EU will only be assessed by one "reporting" member state, which may also result in advantages for herbal medicinal products. One success factor for authorisation is the dossier to be submitted (Investigational medicinal product dossier, IMPD), which must take into account the specifics of herbal medicinal products.

---

### Navigating the future of clinical development

15:30 - 16:15

- Lessons learned with CTAs: What has the industry achieved, and what are the pitfalls to avoid?
- HTA: Where and how? A strategic dive into the health technology assessment and its pivotal role
- Main challenges ahead: Insights into the hurdles shaping tomorrow's clinical development of cannabis-based medicines

Ana Serrato  
(Avextra Pharma GmbH)

As the clinical development landscape grows increasingly complex, adapting to emerging trends and regulatory frameworks is essential. The integration of real-world data and robust scientific evidence is becoming a cornerstone for supporting decision-making, but challenges persist in ensuring data quality and consistency. For cannabis-based medicines (CBMs), the regulatory pathway adds another layer of complexity, as it can vary significantly and has not yet been fully clarified. Similarly, health technology assessments (HTAs) are playing a more prominent role, requiring early alignment and strategic planning. By examining past lessons with CTAs and addressing the main challenges on the horizon, we can build more robust, efficient, and patient-oriented development pathways.





# Cannabis Conference 2025

## CMC considerations for cannabis-based herbal medicinal products

09:00 - 10:00

- Pros and cons for different types of herbal preparations to be developed as API (quantified vs. standardised)
- Pros and cons for different types of extraction solvents
- Scalability of extract preparation
- Value chain and GACP/GMP requirements

Dr. Markus Veit  
(Alphatopics GmbH)

Cannabis-based herbal medicinal products can generally contain standardised or quantified preparations as active ingredients. In development projects, the focus should be placed on quantified preparations, as these cannot be easily copied for the development of generics. In this context, a number of aspects need to be considered, resulting in pros and cons for both types of preparations. It must always be borne in mind that preparations made from cannabis are multi-component mixtures and therefore a comprehensive characterisation of such preparations is already required in the non-clinical development phases in order to ensure the traceability of the data. This is also of central importance if reference is to be made to bibliographic non-clinical or clinical data from third parties. In this context it is always necessary for applicants to be able to justify in a comprehensible manner why they consider data obtained with other preparations to be representative for a given development project. There are a number of other particularities that arise from the presence of multi-component mixtures in development projects. In this presentation, success factors and pitfalls will be presented in equal measure and advice will be given on how to avoid the latter.

---

## Formulation development for oral dosage forms of cannabis-based medicinal products

10:00 - 10:45

- General requirements for pharmaceutical development
- How to improve biopharmaceutical characteristics of cannabis preparations in oral dosage forms
- Case studies

Dr. Norbert Pöllinger  
(Glatt Pharmaceutical  
Services GmbH & Co. KG)

The oral bioavailability of cannabinoids from the initial cannabis preparations, such as extracts, is poor. This is generally also true for the oromucosal administration, as at least part of the administered dose can be swallowed and is therefore not absorbed in the oral cavity. In pharmaceutical development, there is now a spectrum of possibilities for improving the biopharmaceutical properties through appropriate formulations - this applies equally to liquid and solid oral dosage forms. In this presentation case studies will be used to illustrate how suitable formulation platforms can help to achieve oral cannabis-based products with an optimised bioavailability.



# Cannabis Conference 2025

## Considerations for pharmaceutical development of cannabis-based drug-device combination products for inhalation

**11:15 - 12:00**

- Possibilities of inhalative administration
- Pharmaceutical development with inhalative drug-device combination products
- Specific data and studies needed

Thomas Weuthen  
(Actarmo Medical GmbH)

The inhalative administration of cannabis-based medicinal products is an important option when a rapid onset of action is desired in acute situations. There are a number of specifics that need to be considered when developing such orally inhalable products. These are well established for directly inhalable products in the EU. These include the particle or droplet size distribution of the dose, its aerodynamics and disposition, uniformity of dosage and a series of functionality tests of the medical devices used for administration as well as data on compatibility. Such (generally recognised) concepts do not exist for vaporisation as a route of administration and have yet to be developed. The presentation will provide an overview of the data to be established during pharmaceutical development and the areas of tension for administration by vaporisation.

---

## Regulatory pathway for drug-device combination products (DDCPs)

**12:00 - 13:00**

- Types of DDCPs
- Notified Body Opinion
- Dossier requirements
- Considerations for clinical development

Dr. Armin Prasch  
(Trias Pharma GmbH)  
& Dr. Markus Veit  
(Alphatopics GmbH)

Inhaled administration takes place via so-called integral combination products, in which the medical device is used to administer the medicinal product. The EU Medical Device Regulation (MDR) has resulted in a whole series of new or now clearly defined requirements. These products are regulated as medicinal products and are authorised accordingly. However, Art. 117 of the MDR stipulates that the authorisation application for an integral medicinal product/medical device combination must contain information and data for the medical device component and its assessment. This assessment ("Notified Body Opinion") is carried out by Notified Bodies. At the same time, there is a range of specific information to be implemented in the medicinal product dossier or the IMPD. The speakers will provide an overview of this complex of topics.



# Cannabis Conference 2025

## Cannabis extracts – what is state of the art?

- Types of cannabis extracts
- Purification of cannabis extracts
- Terpenoids in cannabis extracts
- How to archive batch-to-batch consistency

**14:00 - 14:45**

Michael Sassano  
(Somaï Pharmaceuticals)

Cannabis extracts are complex multi-component mixtures. If they are to be used as active ingredients in authorised herbal medicinal products, they must fulfil a number of distinct requirements. Of central importance here is batch-to-batch conformity, which must also be scalable in the course of development projects. Furthermore, it is sensible to preserve desirable ingredients during extraction from the genuine plant material and, if necessary, to enrich desirable and purge undesirable ones within the scope of the development of quantified and standardised extracts. This applies not only to cannabinoids, but also to terpenes and possibly flavonoids as well as other groups of constituents. This requires modern extraction techniques and detailed process knowledge. The presentation is intended to provide an insight into what is already possible today and where the challenges lie in the future.

---

## Regulatory data protection and possibilities and limitations of IP protection in development projects

**14:45 - 15:30**

Regulatory data protection and market exclusivity in the European law  
Possibilities and limitations of IP protection  
Future development ("Pharma Package")

Dr. Xenia Boergen  
(European Patent Attorney, Boergen Rechtsanwaltskanzlei)

Pharmaceutical innovations and the necessary investments for that purpose can be protected against imitation through patent protection and regulatory data protection, thus giving companies the opportunity to recoup their previous research and development costs. Both protection mechanisms work in parallel and are limited in time with different concepts. Patents must be applied for at a very early stage of development, and it is therefore necessary to already evaluate the various options for patents in the planning phase. In the case of herbal active ingredients, multiple possibilities in the value chain exist to prevent or at least impede the development of generics in the future. This is also something to be evaluated and established in development projects from the outset. In all cases, the aim is to prevent competition from products with the same or similar active ingredient for as long as possible.

---

## Panel and wrap-up with all speakers

**15:30 - 16:30**



## THE SPEAKERS

**Dr. Xenia Boergen**, Boergen Rechtsanwaltskanzlei, is a lawyer and European Patent Attorney and has been consulting pharmaceutical and biotechnology companies for many years, primarily on contracts, pharmaceutical law, cell and gene therapies and patents/the protection of industrial property rights. She has worked for pharmaceutical and biotech companies as well as for an international law firm and a university hospital. She studied biochemistry and biotechnology in London and Paris and law in Berlin.

**Dr. Simone Breitkopf**, DGPharMed e. V., is a licensed medical doctor, trained in neurology, psychiatry and psychotherapy, with more than 25 years of professional experience within healthcare, including clinical medicine, pharmaceutical and medical device industry and the German pharmaceutical industry association, BPI. In 2018, Dr. Breitkopf founded her own consultancy advising healthcare industry, scientific associations and further institutions in all challenges concerning pharmaceutical medicine, clinical research and market access. She is engaged in several industry and scientific associations, including DGPharMed e. V., where she is a board member and acts as an official delegate to IFAPP.org and German AWMF.org and to the newly founded Registry Working Group within the TMF e. V.

**Dr. Marcel Daas**, Dr. Ebeling & Assoc. GmbH, works as a medical-scientific employee at Dr. Ebeling & Assoc. GmbH, a service provider for the health care industry specialising in medical science, medical affairs and pharmacovigilance. Since September 2023, he has been working there in the field of medical writing, in particular in the creation of "Biocompatibility Evaluation Reports" (BERs) in accordance with the new regulation (EU) 2017/745, MDR. He supports pharmaceutical companies in the creation of medical evaluations of individual case safety reports and their causality assessments in case of potential side effects. He also works in drug safety by conducting regular literature searches as part of a concept for GVP-compliant signal detection and continuous benefit-risk assessment. He completed his studies at the Bonn-Rhein-Sieg University of Applied Sciences in Applied Biology and at the Rhineland-Palatinate Technical University of Kaiserslautern-Landau (formerly the Technical University of Kaiserslautern) in Molecular Cell Biology and Neurobiology. He then worked as a research associate at the University of Greenwich in the UK, where he completed his doctorate in neural stem cell research and human brain development in 2022.

**Dr. Norbert Pöllinger**, Glatt Pharmaceutical Services GmbH & Co. KG, studied pharmacy at the University of Erlangen, Germany and received his PhD degree in Pharmaceutical Technology. After eight years with Bayer's pharmaceutical development and clinical supplies team in Leverkusen he joined Glatt in 1995. Until 2020, he was responsible for Glatt Pharmaceutical Services GmbH & Co.KG in Binzen, Glatt's CDMO organisation in Germany. His activities focused on pharmaceutical development and manufacturing services as well as new technologies. Retired in 2021, he is now active as a senior consultant. His area of expertise is oral dosage forms. One focus is placed on multiparticulate applications, such as pellets and micropellets. Another focus is the optimisation of API solubility and bioavailability using different technology platforms such as amorphous solid dispersions (ASD) and solubiliser-based solid dispersions and self-emulsifying systems.

**Dr. Armin Prasch**, Trias Pharma GmbH, is founder and CEO of Trias Pharma GmbH. Trias Pharma is a specialised consultancy company in the field of pharmaceutical product development with a focus on CMC development services. During his more than 25-year career in the industry, he has designed and built international R&D teams and business development organisations from scratch within the companies Glatt Pharmaceutical Services, ADD Technologies Ltd. and Aenova in the areas of pharmaceutical and analytical development, drug regulatory affairs and clinical trials. As founder and co-partner of Fidelio Healthcare Management Beteiligungs GmbH, Armin Prasch coordinates the strategic direction of the development projects of Fidelio Healthcare Limburg GmbH, a pharmaceutical contract manufacturer. Armin Prasch is on the board of the Branchenverband der Cannabiswirtschaft e.V. (German Cannabis Business Association, BvCW), where he heads the Medicinal Cannabis Division, and he is a member of the "Medicinal Cannabis" expert group under the umbrella of the DPPhG. Armin Prasch studied process engineering at the Technical University of Munich and completed his doctorate in the field of biotechnology.

**Michael Sassano**, Somaí Pharmaceuticals, was one of the first investors in the cannabis industry in the United States; today he is celebrated in the mainstream and biopharmaceutical media as an international authority on the development of large-scale cannabis infrastructure around the world and the most advanced pharmaceutical cannabinoid products.



Mr. Sassano is also respected for his successful predictions of long-term cannabis market trends and movements, which he generously shares in many forums. He is known for leading a merger of the cannabis cultivation company Solaris Farms, which he founded and operated, with The Sanctuary. In recent years, Michael has shifted his focus to his role as CEO and Chairman of the Board of SOMAÍ Pharmaceuticals, a leading EU GMP-compliant, vertically integrated, multi-country operator (MCO) company with a global distribution presence for the largest and most advanced EU GMP-certified cannabinoid pharmaceutical extract portfolio. Michael Sassano's primary goal for SOMAÍ is to build a leading global brand with the most robust pipeline of innovative cannabis-based therapeutics.

**Ana Serrato**, is an experienced pharmaceutical executive with extensive expertise in innovative therapies, orphan drugs, and, more recently, cannabinoid-based medicines (CBMs). With over 20 years of experience in the pharmaceutical and biotechnology industry, she has held various leadership roles at both national and regional levels in major pharmaceutical companies and biotech startups. Originally from Colombia, Ana relocated to Germany in 2019 to take on the role of Global Pharma Head at Clever Leaves. She later joined Avextra Pharma, where she currently leads the Clinical Development Team, driving innovative research and development in CBMs. A passionate advocate for CBM research and scientific data-driven initiatives, Ana is dedicated to advancing patient-oriented guidelines. She works tirelessly to promote accessible and compassionate medical solutions across Europe. Since 2024 she has been Chairwoman for EUMCA (European Medical Cannabis Association). Ana holds a degree in microbiology from the Universidad de los Andes in Bogotá, Colombia, and a Master's Degree in Business Administration from the Universidad Carlos III in Madrid, Spain.

**Dr. Markus Veit**, Alphatopics GmbH, is the Managing Director of ALPHATOPICS GmbH. He studied pharmacy in Frankfurt, obtained his doctorate at the Julius-Maximilians-Universität in Würzburg and habilitated there. From 2003 to 2024, he taught as an adjunct professor at Goethe University Frankfurt. He is a specialised pharmacist for pharmaceutical analysis. He has been a member of the "Pharmaceutical Chemistry" expert committee of the German Pharmacopoeia Commission and various expert groups at the EDQM for over 25 years. Over the past 25 years, he has worked as a founder

and managing director in service companies for the pharmaceutical industry, specialising in drug development, testing of medicinal products and drug regulatory affairs. At the same time, he has conceptually designed and led numerous training and further education events for employees in the pharmaceutical and medical device industry.

**Thomas Weuthen**, is the CEO of Actarmo Medical GmbH. Actarmo Medical is a CRO for GMP testing and development of inhalation products in the pharmaceutical sector. In addition, Actarmo Medical GmbH also offers consulting services for the Medical Device Regulation (MDR) and on inhalation products. In addition to CMC and regulatory activities, this also includes the transfer of customer projects to contract manufacturers. Before his current position, Thomas Weuthen held various roles at Sandoz AG, where he was responsible for the development of dry powder inhalers and asthma sprays for the European and American markets. These activities included pharmaceutical development, clinical studies and the marketing authorisation of products. Mr. Weuthen was also responsible for the global portfolio of respiratory products at Sandoz.

**Dr. Jacqueline Wiesner**, is a research associate and has been working at the BfArM since 2001 as a preclinical assessor in the field of "Herbal and Traditional Medicinal Products". Since 2016, she has been head of the department "Vitamins, Minerals and special therapeutic areas" at BfArM. Since 2010, she has been the German representative on the EMA HMPC and an observer for the HMPC in various other EMA working groups, e.g. the Joint CVMP/CHMP ad hoc expert group on 3Rs (JEG 3Rs), the excipients drafting group and the Non-clinical Working Party.

**Register now, take  
advantage of the early  
bird rate and secure  
your place**



# REGISTRATION & CONTACT

## Online Registration and Further Information:

### Participation Fee (Regular Price) €1,990.00 plus VAT

This includes: Stationery for participants, unlimited coffee and tea, soft drinks outside the conference room, coffee breaks with sweet, savory, and healthy options, and lunch as a seasonal buffet, including all non-alcoholic beverages.

All participants will receive the conference materials and, if applicable, additional documents as printable PDF files on a USB stick.

### Folder Order upon Request:

For a printing fee of €20 per item, participants can receive all presentations in printed form in an A4 binder, in addition to the USB stick, upon prior request. Please contact us separately for this. Thank you.



[www.alphatopics.de](http://www.alphatopics.de)

**Early Bird Price until January 31, 2025: €1,490.00 (excl. VAT) per person**

**Regular Price from February 1, 2025: €1,990.00 (excl. VAT) per person**

For simultaneous bookings of multiple participants from the same company, we offer a 10% discount on the applicable event price for the 2nd, 3rd, etc. participant. A 10% government discount is standard for all our events.

**Birte Doering and Daniela Müller will be happy to help you with your booking and are available to answer any further questions you may have.**

**Office hours Alphatopics:** Monday to Thursday from 8:00 a.m. to 1:00 p.m.

+49 8191 9737-130

[info@alphatopics.de](mailto:info@alphatopics.de)

[www.alphatopics.de](http://www.alphatopics.de)

## EVENT LOCATION & ACCOMMODATION

### Alphatopics Cannabis Conference 2025:

#### The venue in Berlin

The hotel is located in a prime location on the world-famous Friedrichstraße, close to Berlin's most famous attractions and shopping opportunities. A place for first-class conferences and a relaxing stay – where business and comfort come together in perfect harmony.

**NH Collection Berlin Mitte Friedrichstrasse**  
**Friedrichstr. 96**  
**10117 Berlin**



WELCOME TO BERLIN!



ALPHATOPICS GmbH  
Iglinger Straße 27  
86916 Kaufering/Germany  
info@alphatopics.de  
www.alphatopics.de



ALPHATOPICS  
CONFERENCE